These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 20092221)

  • 21. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
    Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
    Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
    Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
    Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tapentadol - A representative of a new class of MOR-NRI analgesics.
    Zajączkowska R; Przewłocka B; Kocot-Kępska M; Mika J; Leppert W; Wordliczek J
    Pharmacol Rep; 2018 Aug; 70(4):812-820. PubMed ID: 29921501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.
    Tzschentke TM; Christoph T; Kögel BY
    CNS Drugs; 2014 Apr; 28(4):319-29. PubMed ID: 24578192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New Opioid Options in Japan - Methadone, Tapentadol and Hydromorphone].
    Takagi Y; Aruga E
    Gan To Kagaku Ryoho; 2018 Feb; 45(2):205-211. PubMed ID: 29483406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Conversion to tapentadol PR improves analgesia and quality of life in patients with severe and chronic pain despite using tramadol > 300 mg/d].
    Richter U; Waldmann-Rex S; Lehmann U
    Wien Klin Wochenschr; 2015 Jun; 127(11-12):477-87. PubMed ID: 25409951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.
    Kleinert R; Lange C; Steup A; Black P; Goldberg J; Desjardins P
    Anesth Analg; 2008 Dec; 107(6):2048-55. PubMed ID: 19020157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview].
    Tzschentke TM; Christoph T; Schröder W; Englberger W; De Vry J; Jahnel U; Kögel BY
    Schmerz; 2011 Feb; 25(1):19-25. PubMed ID: 21258822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro and in vivo characterization of tapentadol metabolites.
    Terlinden R; Kogel BY; Englberger W; Tzschentke TM
    Methods Find Exp Clin Pharmacol; 2010; 32(1):31-8. PubMed ID: 20383344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-term opioid therapy in chronic noncancer pain. A systematic review and meta-analysis of efficacy, tolerability and safety in open-label extension trials with study duration of at least 26 weeks].
    Häuser W; Bernardy K; Maier C
    Schmerz; 2015 Feb; 29(1):96-108. PubMed ID: 25503691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings.
    Alshehri FS
    Drug Des Devel Ther; 2023; 17():851-861. PubMed ID: 36974332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study of dezocine, pentazocine and tapentadol on antinociception and physical dependence.
    Ahsan MZ; Zhao MJ; Shoaib RM; Zhang Y; Wang YX
    Life Sci; 2021 Nov; 285():119996. PubMed ID: 34597607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unique pharmacology of tapentadol for treating acute and chronic pain.
    Knezevic NN; Tverdohleb T; Knezevic I; Candido KD
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1475-92. PubMed ID: 26215077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
    Schiene K; De Vry J; Tzschentke TM
    J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of tapentadol with tramadol for analgesia after cardiac surgery.
    Iyer SK; Mohan G; Ramakrishnan S; Theodore S
    Ann Card Anaesth; 2015; 18(3):352-60. PubMed ID: 26139740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tramadol as an analgesic for mild to moderate cancer pain.
    Leppert W
    Pharmacol Rep; 2009; 61(6):978-92. PubMed ID: 20081232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine].
    Bono AV; Cuffari S
    Drugs; 1997; 53 Suppl 2():40-9. PubMed ID: 9190324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Tapentadol. Opioid analgesic and norepinephrine reuptake inhibitors].
    Weichel C; Hecht B
    Med Monatsschr Pharm; 2010 Dec; 33(12):454-60. PubMed ID: 21189520
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
    Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
    Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The novel compound (+/-)-1-[10-((E)-3-Phenyl-allyl)-3,10-diaza-bicyclo[4.3.1]dec-3-yl]-propan-1-one (NS7051) attenuates nociceptive transmission in animal models of experimental pain; a pharmacological comparison with the combined mu-opioid receptor agonist and monoamine reuptake inhibitor tramadol.
    Munro G; Baek CA; Erichsen HK; Nielsen AN; Nielsen EØ; Scheel-Kruger J; Weikop P; Peters D
    Neuropharmacology; 2008 Feb; 54(2):331-43. PubMed ID: 18037451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.